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Multidrug resistance (MDR) is a major clinical obstacle in treatment of gastric cancer. Previously, using 2D
electrophoresis-mass spectrometry, we identified RhoGDI2 as a contributor to 5-FU resistance in colon cancer cells,
and also confer gastric cancer cells resistance to 5-FU. Here, we reported RhoGDI2 also induced MDR in gastric
cancer cell line (MKN-45). To explore the underlining mechanism, we detected the mRNA, protein expression,
activity of P-glycoprotein (P-gp) in MKN-45 stably transfected with RhoGDI2 expressing or control vector. All the
mRNA, protein level, activity were increased by 130%, 230%, 35% respectively after ectopic expression of RhoGDI2.
RhoGDI2 was correlated with P-gp expression in gastric cancer tissues as detected by immunohistochemistry. To
further study how RhoGDI2 up-regulates P-gp expression, we tested the activity of Rac1 in MKN-45/RhoGDI2 and
MKN-45/GFP. Ectopic expression of RhoGDI2 increased Rac1 activity (P < 0.05). For more important, silencing of
Rac1 expression by siRNA decreased P-gp expression to undetectable level. Overall, these findings suggest that
RhoGDI2 up-regulates P-gp expression via Rac1 to induce MDR.
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Gastric cancer is the fourth most common type of cancer
and the second leading cause of cancer-related deaths in
the world [1]. Chemotherapy plays an important role in
the treatment of gastric cancer both in adjuvant and ad-
vanced settings. However, the efficacy of chemotherapy
for gastric cancer is limited due to insensitivity and the
development of multi-drug resistance (MDR). Numerous
efforts have been made to understand the mechanisms
underlying MDR. [2] It is known that MDR involves a
large number of molecules and complex mechanisms.
Classical drug-resistant molecules, such as P-glycoprotein
(P-gp)/ABCB1 and multi-drug resistance protein (MRP1)/
ABCC1, have been found to play important roles in me-
diating MDR in some gastric cancers [3]. To reveal the
mechanisms underlying drug resistance, we previously
compared the proteomic profiles of 5-FU resistant and
sensitive colon cancer cells by 2-D gel electrophoresis
[4]. We found that RhoGDI2 was up-regulated in 5-
fluorouracil (5-FU) resistant colon cancer cells (LoVo/* Correspondence: docwuxh@hotmail.com
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unless otherwise stated.5-FU) and that the knockdown of RhoGDI2 expression
by transfection with RhoGDI2-specific siRNA signifi-
cantly increased sensitivity to 5-FU in LoVo/5-FU [4].
These data suggested that RhoGDI2 confers resistance
to 5-FU in colon cancer cells. Later on, our and other
groups also showed RhoGDI2 play important role in
multi-drug resistance in gastric cancer [5-9].
RhoGDI2 belongs to a family of Rho GTPase dissoci-
ate inhibitors (GDIs). GDIs are pivotal regulators of Rho
GTPase function typified by forming a complex with
Rho GTPase, modulating their nucleotide exchange and
membrane association. Therefore, they play an import-
ant role in regulating the actin cytoskeleton, cell polarity,
microtubule dynamics, membrane transport pathways,
and transcription factor activity [10,11]. Unlike other
members (RhoGDI1, RhoGDI3), RhoGDI2 is preferen-
tially expressed in hematopoietic cells and overexpressed
in gastric cancer it also appears to have a narrow select-
ivity and lower binding affinity for Rho GTPases [12].
RhoGDI2 associates with and negatively regulates Rac1
and Rac3 in breast cancer cells, but not RhoA, Cdc42,
and RhoC [13], whereas it positively regulates Rac1 in
human bladder cancer cells [14].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cleaved in various cell types during apoptosis. Recently,
several lines of study reported the important role of
RhoGDI2 in multi-drug resistance in gastric cancer
[4-9]. A Korea group showed RhoGDI2 confer gastric
cancer cells resistance to cisplatin induced apoptosis by
several mechanisms. VEGF-C [7], 14-3-3σ [8], PLCγ [5],
Bcl-2 [6] may mediate the effects of RhoGDI2 in drug
resistance. However, our previous study showed a differ-
ent mechanism [9]. RhoGDI2 reverted the low dose 5-
FU-induced G2/M arrest rather than high dose 5-FU
induced apoptosis [9]. Here we reported another new
mechanism by which RhoGDI2 induced MDR, which is
that RhoGDI2 upregulates P-gp expression via Rac1.
Results
Ectopic expression of RhoGDI2 up-regulates P-gp
expression
To determine the role of RhoGDI2 in drug resistance, we
established a gastric cancer cell line (MKN-45/RhoGDI2)
stably transfected with a RhoGDI2 expression vector.
Ectopic expression of RhoGDI2 in MKN-45 increased
RhoGDI2 protein and mRNA expression by 58 and 1.6
fold respectively (Figure 1a and b, both P < 0.01). The pre-
vious study showed ectopic expression of RhoGDI2 conferFigure 1 Ectopic expression of RhoGDI2 increased P-gp mRNA, protein an
in MKN-45/RhoGDI2 and MKN-45/GFP. The immunoblot image was quantit
*p < 0.05 vs MKN-45/GFP. (b) The mRNA of RhoGDI2 (left) and P-gp (right)
(c) P-gp activity in MKN-45/RhoGDI2 and MKN-45/GFP was measured as d
expressed as mean ± SD from three independent experiments; *p < 0.001MKN-45 resistance to 5-FU. In addition to that, the IC50
of doxorubicin, Paclitaxel was increased in MKN-45
from 0.23 ± 0.011μM to 0.31 ± 0.025μM (P < 0.05) and
from 4.9 ± 0.33 to 8.5 ± 0.60nM (P < 0.05) respectively
after ectopic expression of RhoGDI2. To investigate the
mechanisms underlying RhoGDI2 induced multi-drug
resistance, we compared the mRNA levels of several
MDR related genes expression by RT-PCR including Mdr-
1, multi-drug resistance protein 1 (MRP-1), MRP-2, MRP-
3, MRP-4, MRP-5, MRP-8 between MKN-45/RhoGDI2
and MKN-45/GFP (Additional file 1 Figure S1). The levels
of Mdr-1 (Figure 1b) mRNA was the only one significantly
increased in MKN-45/RhoGDI2 by 1.3 fold. Protein level
of Mdr-1 gene (P-gp) was increased by 2.3 fold in MKN-
45/RhoGDI2, comparing with MKN-45/GFP (Figure 1a,
P < 0.05). In addition to that, the P-gp activity of MKN-
45/RhoGDI2 was also increased by 32.5%, comparing
with MKN-45/GFP (Figure 1c, P < 0.05).
RhoGDI2 correlates with P-gp expression in human
gastric cancer tissue
To determine whether there was a correlation between
the expression of RhoGDI2 and P-gp in patients with
gastric cancer, RhoGDI2 and P-gp levels in gastric can-
cer tissues were analysed by IHC. As shown in previousd activity. (a) Western blotting analysis of RhoGDI2 and P-gp expression
ated by densitometric analysis (right) (n = 3 independent experiments).
in MKN-45/RhoGDI2 and MKN-45/GFP was detected by RT-PCR.
escribed in materials and methods, MAF was plotted. Data are
vs MKN-45/GFP.
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cells [9]. P-gp was present in the membrane of both can-
cerous and adjacent benign gastric epithelial cells. There
was no significant difference of the P-gp levels between
cancer and benign tissues. Interestingly, the expression
of RhoGDI2 was correlated with P-gp expression only in
cancerous tissue (p = 0.011, χ2 = 7.46). Co-expression of
RhoGDI2 and P-gp was also frequently observed in can-
cer cells (Figure 2).
RhoGDI2 up-regulates P-gp expression via Rac1
It is reported the RhoGDI2 is associated with Rac1 and
regulates its activity [13-17]. Therefore, we tested the
Rac1 activity in MKN-45/RhoGDI2 and MKN-45/GFP
by ELISA based quantification of active Rac1 (Rac1-
GTP) level. The Rac1 activity was increased in MKN-45/
RhoGDI2 by 1.6 fold, comparing with MKN-45/GFP
(Figure 3a, P < 0.05). Next, we test whether Rac1 is re-
quired for up-regulation P-gp by RhoGDI2 overexpres-
sion. Transfection of Rac1 siRNA for 48 hours decreased
Rac1 expression in both MKN-45/RhoGDI2 and MKN-
45/GFP cells (Figure 3b). P-gp level was also significantly
decreased after silencing of Rac1 expression in both
MKN-45/RhoGDI2 and MKN-45/GFP cells (Figure 3b).
It indicates the effects of RhoGDI2 induced P-gp upreg-
ulation was abolished by inhibition of Rac1.
Discussion
In our previous study using 2D electrophoresis-mass spec-
trometry, we found that RhoGDI2 was a contributor to 5-
FU resistance in colon cancer [4]. Later on, we showed
that RhoGDI2 also confers resistance to 5-FU in gastric
cancer cells [9]. Here we reported a new mechanism byFigure 2 Representative images of IHC staining with anti-P-gp and anti-Rh
sections of gastric cancer tissue. Serial sectioning slices were stained with a
positive of staining, the negative staining was contra-stained with hematox
stained with both anti-P-gp and anti-RhoGDI2. RhoGDI2 is expressed major
the cancerous cells expressed high RhoGDI2 also were positively stained w
cells with lower RhoGDI2 were also weakly stained with anti-P-gp (shown i
and RhoGDI2 (marked with triangle). Magnification 400×. Scale bar = 100 μwhich RhoGDI2 induces multidrug resistance. It is that
RhoGDI2 up-regulates P-gp expression via Rac1.
Accumulative evidence show that RhoGDI2 confer
multi-drug resistance in ovarian cancer, gastroenterolo-
gic cancer [4-9], breast cancer [13]. It was shown that
RhoGDI2 was over-expressed in chemo-resistant fibrosar-
coma cells and paclitaxel-resistant ovarian cancers, respect-
ively [18,19]. Hee et al. [6] reported that RhoGDI2 confers
resistance against multiple chemotherapeutic agents (cis-
platin, etoposide, and staurosporin) -induced apoptosis in
gastric cancer cells. Together with our results, we conclude
that high levels of RhoGDI2 expression are associated with
chemotherapy resistance in certain types of cancers, like
gastroenterologic cancer.
P-gp, the product of the ABCB1 (mdr-1) gene, is a full
transporter comprised of 12 transmembrane segments
divided into TM domains, each linked with an ATP-
binding domain [20]. It was first identified due to its
overexpression in drug-resistant tumor cells, where it
functions as a broad range drug transporter, thereby con-
ferring resistance to many important chemotherapeutic
agents including vinblastine, doxorubicin, and paclitaxel
[20,21]. Here, we reported that ectopic expression of
RhoGDI2 increased P-gp expression and activity in gastric
cancer. Furthermore, in patients with gastric cancer, the
expression of RhoGDI2 was also positively associated with
P-gp expression in cancer cells. Our previous study showed
RhoGDI2 reverted the low dose 5-FU-induced G2/M ar-
rest. Taken all these together, RhoGDI2 confers multi-drug
resistance in gastric cancer by multiple mechanisms. Rho
GTPase plays important roles in regulation of astral micro-
tubules and the interaction of spindle microtubules with
chromosomes during mitosis. It is reported inhibition ofoGDI2 demonstrate the co-expression of P-pg and RhoGDI2 in serial
nti-P-gp and anti-RhoGDI2 from one case. Brown color represent
ylin and shown in blue color. Most of the cancer cells were positively
ly in nuclear, whereas P-gp majorly presents in membrane. Some of
ith anti-P-gp (shown in solid arrow), whereas some of the cancerous
n dashed arrow). The non-cancerous cells are negative for both P-gp
m.
Figure 3 RhoGDI2 up-regulates P-gp expression via Rac1. (a) Rac1 activity in MKN-45/RhoGDI2 and MKN-45/GFP was measured as described in
materials and methods. Data are expressed as mean ± SD from three independent experiments; *p < 0.001 vs MKN-45/GFP. (b) Western blot
analysis of P-gp and Rac1 expression in MKN-45/RhoGDI2, MKN-45/GFP transfected with Rac-1 or Mock siRNA (pictures are representative of three
independent experiments). The immunoblot image was quantitated by densitometric analysis (c) (n = 3 independent experiments). Data was
shown in folds relative to MKN-45/GFP + NC siRNA. *p < 0.05 vs MKN-45/GFP + NC siRNA, #p < 0.05 vs MKN-45/RhoGDI2 + NC siRNA.
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RhoGDI2 up-regulates P-gp transcription via Rho GTPase
(Rac1). Hence it is possible the versatile Rho GTPase
contributes to the multiple mechanisms underlining
RhoGDI2 induced MDR.
Rac1 was recognized as the important co-operator of
RhoGDI2 and mediator of its function [16]. Unlike other
member of Rho GTPase, RhoGDI2 preferentially binds
to Rac1 and affects its activity [16]. A recent study showed
RhoC was also regulated by RhoGDI2 [22]. However,
numerous studies have shown the conflicting role of
RhoGDI2 in the regulation of Rac1 dependenting on the
tumour types and/or cellular microenvironment. it is dem-
onstrated that RhoGDI2 inhibited Rac1 activity in MDA-
MB-231 human breast cancer cells [13] and mouse em-
bryonic fibroblasts [23], whereas others showed RhoGDI2
acted as a positive regulator of Rac1 in T24 and UMUC3
human bladder cancer cells [14], H9c2 cardiomyoblast
cells [17] and ovarian cancer. Both Cho et al. and our
results demonstrated that RhoGDI2 up-regulated Rac1 ac-
tivity [7] in gastric cancer cell lines. The mechanisms bywhich RhoGDI2 regulates Rac1 aren’t fully understood.
Boulter et al described an evolutionarily conserved mech-
anism by which RhoGDI1 controls the homeostasis of
Rho proteins in eukaryotic cells [24]. They showed that
depletion of RhoGDI1 led to destabilization and degrad-
ation of unbound RhoGTPases resulting in a reduction of
GTPase protein levels, while unexpectedly activating
the remaining membrane bound fraction [24]. It isn’t
clear whether RhoGDI2 function in a similar manner as
RhoGDI1 to protect Rho family GTPases from degrad-
ation. Huang et al [17] reported in cardiomyoblast cell
line H9c2 unlike RhoGDI1, RhoGDI2 up-regulates Rac1
mRNA transcripts, rather than Rac1 protein stability.
Our and other studies didn’t show alteration of RhoGDI2
expression could results in Rac1 protein level change in
cancer cells [7,13,14]. Therefore it is expected RhoGDI2
might act in a different way to regulate Rac1. Extraction
Rho GTPases from the membrane by RHOGDIs is the
second mechanism to regulated RHO GTPase activity
[16,25]. In Breast cancer cells MDA-MB-231, knockdown
of RhoGDI2 results in Rac1 translocation from the cytosol
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tive Rac1 activation and cell growth inhibition [13]. In
contrast in bladder cancer, RhoGDI2 activated Rac activity
without affecting Rac membrane/cytosol ratios [14]. How-
ever, point mutants of RhoGDI2 that increase or decrease
the affinity of RhoGDI2 for GTPases abolished its ability
to activate Rac [26]. It indicates there is a mechanism dis-
tinct from inhibition of membrane association involved in
activation of Rac1 by RhoGDI2. Recently, using system
biological method, a model was constructed to reveal how
RhoGDIs act as positive regulators of Rho GTPase [27]. It
indicates RhoGDIs positively regulate Rho GTPase signal-
ing primarily by interacting with GAPs and may partici-
pate in the switching between transient and sustained
signals of the Rho GTPases. It need further study to con-
firm whether and which GAPs are involved in our study.
In conclusion, we suggest that there is a new mechan-
ism by which RhoGDI2 contribute to multi-drug resist-
ance in gastric cancer cells. It may effects drug efflux by
up-regulation of P-gp expression via Rac1, rather than dis-
turbance the apoptotic pathway as shown by other group.
Material and methods
Cell culture
Human gastric cancer cell lines MKN-45 were obtained
from the Chinese Academy of Sciences Cell Bank of
Type Culture Collection (Shanghai, China). All the
gastric cancer cell lines were cultured in RPMI-1640
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS
(PAA Laboratories GmbH, Morningside, QLD, Australia).
Patients and tissues
Human gastric cancer tissue arrays were obtained from
Outdo Biotech (Shanghai, China) with 88 individual cases
of gastric cancer and matched normal colon tissue. The
ethics committee at Ruijin Hospital approved the use of
these tissues for research purposes.
RhoGDI2 expressing plasmid
To generate a RhoGDI2 expression plasmid, the full-
length coding region of RhoGDI2 cDNA was amplified
using the primers RhoGDI2-forward CATACTCGAGCGG
ACA GAG ACG TGAA GCAC and RhoGDI2-reverse
CACTGGATCCGAGT GAC AGG GTG GGA AAAG
(the restriction sites of XhoI and BamHI were italic)
and inserted into pIRES2-EGFP (Clontech Laboratories,
Mountain View, CA) at XhoI and BamHI sites. MKN-45
cells were transfected with pIRES2-EGFP-RhoGDI2 or
pIRES2-EGFP using Lipofectamine 2000 reagent (Invi-
trogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Stable plasmid-transfected clones
were selected using 800 μg/ml G418 (Invitrogen) for 2
weeks, isolated colonies were picked up with tips, and
the cells were further cultured in the presence of 400μg/ml G418. MKN-45 cells transfected with pIRES2-
EGFP-RhoGDI2 were named MKN-45/RhoGDI2 cells.
MKN-45 cells transfected with pIRES2-EGFP were
named MKN-45/GFP cells.
In vitro cytotoxicity assay
The MTT assay was used to determine the relative sensi-
tivity of cell lines to 5-FU (Xudonghaipu Pharmaceutical
Co., Shanghai, China), as described previously [4]. For
cell lines, cells plated in 96-well microplates were cultured
with growth medium or treated with serial dilutions of
5-FU for 72 hours. Viable cells were measured with MTT
(Sigma, St. Louis, MO) and the results were expressed
relative to the absorbance of cells grown in the absence of
drug. IC50 values were calculated by nonlinear regression
analysis from triplicate independent experiments.
Western blot analysis
Western blot analysis was done as previously described
[28]. Briefly, cell lysates were separated by SDS-PAGE
and transferred to a PVDF membrane. The blot was
then probed with anti-RhoGDI2 (LabVision, Fremont,
CA) with a dilution of 1:1000 , anti-P-gp (Santa Cruz
Biotechnology, Santa Cruz, CA) with a dilution of 1:250,
anti-Rac-1 (Sangon Biotech, Shanghai, China ) with a dilu-
tion of 1:500, or anti-ABCC-1 (MRP1) (Sangon Biotech,
Shanghai, China ) with a dilution of 1:250 followed by an
incubation with a horse radish peroxidase-conjugated sec-
ondary antibody. The signal was detected using enhanced
chemiluminescence (Millipore). The expression level was
quantified using Image J program (NIH).
Immunohistochemical staining
Immunohistochemical staining was done as described
previously using a DAKO EnVision + System HRP [29].
RhoGDI2 polyclonal antibody from LabVision (Fremont,
CA) was applied at a 1:2,000 dilution overnight at 4°C,
while anti-P-gp was applied at a 1:200 dilution. Purified
rabbit-IgG was used as an isotype control. The stained
sections were reviewed by two independent observers
who had no prior knowledge of the clinic pathologic
data of the patients. A scoring method was used as re-
ported previously based on the fact that the specimens
clearly showed varying degrees of staining intensity and
percentage of cell staining [30]. Briefly, strong-intensity
staining was scored as 3, moderate as 2, weak as 1, and
negative as 0. For each intensity score, the percentage of
cells with that score was estimated visually. A combined
weighted score consisting of the sum of the percentage
of cells staining at each intensity level was calculated
for each sample. The immunolabelling was categorised
as negative (score > 30) or positive (score ≤30) for all
the tissues.
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Fluorescent probe eFluxx-ID Gold was used to monitor
P-gp functionality. Cells were trypsinized and incubated
for 30 min at 37°C in phenol red free Opti-MEM medium
(Invitrogen) with eFluxx-ID Gold (ENZO Life Sciences,
Lörrach, Germany) according to the manufacturer’s proto-
col. Cells were analyzed by flow cytometry (FACSCanto;
BD Biosciences, Heidelberg, Germany). Each flow cytome-
try analysis consisted of a record of 100,000 cells. The
uptake of eFluxx-ID Gold of EGFP-positive cells was mea-
sured in the FL2 (PE) and FL1 (FITC) channel. Dead cells
were excluded by using scatter parameters. In parallel
experiments, P-gp inhibitor Verapamil was added to the
cells to a final concentration of 20 μM for 30min during
the incubation with eFluxx-ID Gold in order to determine
whether the alterations in eFluxx-ID Gold uptake induced
by transfection with P-gp. Multidrug resistance activity
factor (MAF) was calculated as MAF (MDR1) = 100 ×
(fluorescence intensity with P-gp inhibitor - fluores-
cence intensity without P-gp inhibitor)/ fluorescence in-
tensity with P-gp inhibitor.Rac1 activity assay
For measurement of Rac1 activation in cell lysates from
MKN-45 cells, equal amounts of protein per sample (deter-
mined by use of a Protein Assay Kit from Bio-Rad Labora-
tories; Hercules, CA) were analyzed using the specific Rac1
G-LISA™ Activation Assay Kit (Cytoskeleton; Denver, CO)
according to the manufacturer’s instructions. This lumines-
cence G-LISA™ is an ELISA based assay that allows meas-
uring the GTP-bound (active) form of small G-proteins.
Active Rac1 levels were expressed as fold-increase over the
active Rac1 levels in control conditions.Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
for the Detection of P-gp RhoGDI2 Expression at the
mRNA Level
Expression of human P-gp and RhoGDI2 at the mRNA
level in the cell lines used was verified by reverse tran-
scription of RNA followed by polymerase chain reaction.
RNA was isolated using the Trizol reagent (Invitrogen
Life Technologies, Carlsbad, CA, USA). First-strand cDNA
synthesis was performed with the First-Strand cDNA syn-
thesis kit for RT-PCR (Jrdun biotechnology, Shanghai,
China) with oligo(d T) primers according to the manufac-
turer’s instructions. Primers used for the amplification of
human P-gp were 5′- CGCTGTTCGTTTCCTTTAG -3′
(sense) and 5′- CTTCTTTGCTCCTCCATTG -3′ (anti-
sense). For RhoGDI2, primers were 5'-TTCTTCACCGA
CGATGAC-3' (sense) and 5'-GGAAATGTG GCAGT
GTTG-3' (antisense). For MRPs, see Additional file 2
Table S1. All primers were synthesized by MWG Biotech
AG (Shanghai, China). PCR was performed on the ABIPrism 7300 in a total volume of 50 μl using the Jrdun bio-
technology FQ-PCR kit (Shanghai, China).
Statistical analysis
Statistical analyses of data were performed by using the
Student t-test or one-way analysis of variance, depending
on the number of groups in comparison. Data that failed
the test for normal distribution or homogeneous vari-
ance were analysed using the Mann–Whitney U or the
Kruskal–Wallis tests. The correlation between RhoGDI2
and P-gp expression was analysed using the Fisher exact
test. The statistical software SPSS version 14.0 was used
for analysis. Significance was set at P < 0.05.
Additional files
Additional file 1: Figure S1. A. The mRNA of RhoGDI2 (left) and P-gp
(right) in MKN-45/RhoGDI2 and MKN-45/GFP was detected by RT-PCR.
Data was expressed as relative to GAPDH (mean ±SD) from three
independent experiments; *p < 0.05 vs MNK-45/GFP. B. Western blotting
analysis of MRP-1 expression in MKN-45/RhoGDI2 and MKN-45/GFP.
Additional file 2: Table S1. The primers for MRPs.
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